Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 1
2005 3
2006 5
2007 9
2008 13
2009 21
2010 17
2011 30
2012 21
2013 22
2014 48
2015 76
2016 109
2017 119
2018 143
2019 119
2020 100
2021 114
2022 97
2023 90
2024 95

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,061 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Behnke K, Zhuang Y, Xu HC, Sundaram B, Reich M, Shinde PV, Huang J, Modares NF, Tumanov AV, Polz R, Scheller J, Ware CF, Pfeffer K, Keitel V, Häussinger D, Pandyra AA, Lang KS, Lang PA. Behnke K, et al. Hepatology. 2019 Sep;70(3):1074-1075. doi: 10.1002/hep.30600. Hepatology. 2019. PMID: 30829412 No abstract available.
Noncoding RNAs in B cell non-Hodgkins lymphoma.
Abedi Kichi Z, Dini N, Rojhannezhad M, Shirvani Farsani Z. Abedi Kichi Z, et al. Gene. 2024 Jul 30;917:148480. doi: 10.1016/j.gene.2024.148480. Epub 2024 Apr 16. Gene. 2024. PMID: 38636814 Review.
B-cell non-Hodgkins lymphomas (BCNHLs) are a category of B-cell cancers that show heterogeneity. These blood disorders are derived from different levels of B-cell maturity. Among NHL cases, 80-90 % are derived from B-cells. Recent studies have demonstr …
B-cell non-Hodgkins lymphomas (BCNHLs) are a category of B-cell cancers that show heterogeneity. These blood disorders are der …
Future of Helicobacter pylori and its feasibility.
Talebi Bezmin Abadi A, Kusters JG. Talebi Bezmin Abadi A, et al. Expert Rev Anti Infect Ther. 2018 Oct;16(10):733-735. doi: 10.1080/14787210.2018.1523715. Epub 2018 Sep 17. Expert Rev Anti Infect Ther. 2018. PMID: 30211621 No abstract available.
Inactive Hepatitis B Carrier and Pregnancy Outcomes: A Systematic Review and Meta-analysis.
Keramat A, Younesian M, Gholami Fesharaki M, Hasani M, Mirzaei S, Ebrahimi E, Alavian SM, Mohammadi F. Keramat A, et al. Iran J Public Health. 2017 Apr;46(4):468-474. Iran J Public Health. 2017. PMID: 28540262 Free PMC article. Review.
BACKGROUND: We aimed to explore whether maternal asymptomatic hepatitis B (HB) infection effects on pre-term rupture of membranous (PROM), stillbirth, preeclampsia, eclampsia, gestational hypertension, or antepartum hemorrhage. ...
BACKGROUND: We aimed to explore whether maternal asymptomatic hepatitis B (HB) infection effects on pre-term rupture of membranous (P …
A review of the critical role of vitamin D axis on the immune system.
Daryabor G, Gholijani N, Kahmini FR. Daryabor G, et al. Exp Mol Pathol. 2023 Aug;132-133:104866. doi: 10.1016/j.yexmp.2023.104866. Epub 2023 Aug 17. Exp Mol Pathol. 2023. PMID: 37572961 Free article. Review.
The expression of VDR in immune cells such as dendritic cells, monocyte/macrophage, neutrophils, B cells and T cells has been well demonstrated. Besides, such immune cells are capable of metabolizing the active form of Vit-D which means that it can module the immune system …
The expression of VDR in immune cells such as dendritic cells, monocyte/macrophage, neutrophils, B cells and T cells has been well de …
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Safarzadeh Kozani P, et al. Front Immunol. 2021 Oct 28;12:765097. doi: 10.3389/fimmu.2021.765097. eCollection 2021. Front Immunol. 2021. PMID: 34777381 Free PMC article. Review.
Chimeric antigen receptor T-cell (CAR-T) therapy has been successful in creating extraordinary clinical outcomes in the treatment of hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). With several FDA approva …
Chimeric antigen receptor T-cell (CAR-T) therapy has been successful in creating extraordinary clinical outcomes in the treatment of hematol …
CRISPR, CAR-T, and NK: Current applications and future perspectives.
Khoshandam M, Soltaninejad H, Hamidieh AA, Hosseinkhani S. Khoshandam M, et al. Genes Dis. 2023 Sep 19;11(4):101121. doi: 10.1016/j.gendis.2023.101121. eCollection 2024 Jul. Genes Dis. 2023. PMID: 38545126 Free PMC article. Review.
Despite the success of this approach in refractory B-cell malignancies, the optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been validated. ...
Despite the success of this approach in refractory B-cell malignancies, the optimal potency of CAR T-cell therapy for many other canc …
The role of Pax5 in leukemia: diagnosis and prognosis significance.
Shahjahani M, Norozi F, Ahmadzadeh A, Shahrabi S, Tavakoli F, Asnafi AA, Saki N. Shahjahani M, et al. Med Oncol. 2015 Jan;32(1):360. doi: 10.1007/s12032-014-0360-6. Epub 2014 Nov 27. Med Oncol. 2015. PMID: 25428382 Review.
Pax5 expression is essential in B-cell precursors for normal differentiation and maturation of B-cells. On the other hand, it inhibits the differentiation and progress toward other lineages. The expression of this factor is involved in several aspects of B-ce …
Pax5 expression is essential in B-cell precursors for normal differentiation and maturation of B-cells. On the other hand, it …
Updates on CAR T cell therapy in multiple myeloma.
Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, Molaei S, Gavgani SP, Rahbarizadeh F. Nasiri F, et al. Biomark Res. 2024 Sep 12;12(1):102. doi: 10.1186/s40364-024-00634-5. Biomark Res. 2024. PMID: 39261906 Free PMC article. Review.
In recent developments, the success of chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies exemplifies a new paradigm shift in advanced immunotherapy techniques with promising therapeutic outcomes. ...
In recent developments, the success of chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies exemplifies a new para …
CD40 and tolerance induction.
Karimi MH, Pourfathollah AA. Karimi MH, et al. Iran J Allergy Asthma Immunol. 2012 Mar;11(1):1-13. Iran J Allergy Asthma Immunol. 2012. PMID: 22427471 Free article. Review.
According to these roles, it is assumed that CD40 is a functional molecule in the pathologies of conditions like autoimmune diseases and allograft rejection caused by activated T and B cells....
According to these roles, it is assumed that CD40 is a functional molecule in the pathologies of conditions like autoimmune diseases and all …
1,061 results